Ischemic Stroke Market Size to Reach US$ 5.2 Billion by 2034, Impelled by Advancements in Early Detection

Ischemic Stroke Market Outlook 2024-2034:

The ischemic stroke market size reached a value of US$ 3.0 Billion in 2023. Looking forward, the market is expected to reach US$ 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.24% during 2024-2034. The market is driven by the increased application of cerebral angiography that uses contrast dye to visualize a clear X-ray of blockages or anomalies in the brain blood arteries for diagnosing the illness. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Ischemic Stroke Market 

The growing worldwide incidence of stroke episodes, as well as the rising demand for effective, rapid diagnostic solutions, are driving the ischemic stroke market. Furthermore, one of the most notable advancements is the development of advanced imaging techniques, such as CT and MRI scans, as well as CT and MR angiography and CT and MR perfusion. These approaches have improved thrombolytic therapy decision-making and allowed for more accurate and rapid detection of stroke events, revolutionizing early diagnosis. Furthermore, the introduction of automated imaging software powered by artificial intelligence (AI) has increased the speed and accuracy of identifying ischemic strokes. Another notable advancement is the growing use of biomarkers for early stroke identification. For instance, blood-based biomarkers, such as S100 calcium-binding protein B (S100B) and glial fibrillary acidic protein (GFAP), are being studied for their ability to detect brain damage early in ischemic stroke patients. These biomarkers have the potential to provide rapid, non-invasive diagnosis, which would be especially useful in emergency situations where time is important. Furthermore, the combination of digital health technologies and mobile applications aids in stroke detection. There is a growing trend of wearable technology that can detect atrial fibrillation, a significant risk factor for ischemic stroke, and continually monitor heart rhythms. Patients can receive preventative therapy prior to having a stroke thanks to these devices' assistance in early identification. Apart from this, increased funding for stroke research, strategic collaborations between healthcare providers and technology firms, and a rising focus on personalized medicine are fueling the growth of the ischemic stroke market.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The ischemic stroke market is being transformed by the development of new therapies and pharmaceutical treatments, which have been driven by a growing desire to lessen the burden of this common cerebrovascular disease and improve clinical results. Moreover, one of the most significant advances is the development of neuroprotective medicines targeted at reducing neuronal damage during and after an ischemia event. Calcium channel blockers, free radical scavengers, and anti-inflammatory medicines are examples of possible treatments that target diverse biochemical pathways implicated in ischemia injury. For example, the discovery of innovative medications targeting the N-Methyl-D-aspartate (NMDA) receptors, which play an important role in excitotoxicity-induced neuronal death, shows promise in terms of lowering brain cell damage and enhancing recovery. Another notable improvement is in the field of combination medicines, which seeks to improve the efficacy of existing pharmaceutical agents. In an effort to decrease challenges and increase the therapeutic window, thrombolytic medications are being actively studied in conjunction with neuroprotective or anti-inflammatory substances. Furthermore, customized medical approaches are becoming increasingly popular, with a focus on patient-specific factors like genetic markers and co-morbidities. Pharmacogenomics allows treatments to be tailored to individual genetic profiles, potentially enhancing therapeutic efficacy while lowering side effects. Additionally, gene therapy holds promise as it targets particular genes involved in inflammatory regulation, neuroprotection, and blood flow restoration. This technique attempts to produce long-term therapeutic effects, lowering stroke recurrence and improving recovery.

Marketed Therapies in the Ischemic Stroke Market

Aggrenox (Aspirin/dipyridamole extended release): Boehringer Ingelheim

Aggrenox (Aspirin/dipyridamole extended release) is an antiplatelet medication used to minimize the risk of stroke in individuals with transient ischemia of the brain or
completed ischemic stroke caused by thrombosis. The antithrombotic action of AGGRENOX is due to the combined antiplatelet actions of dipyridamole and aspirin. Dipyridamole reduces adenosine absorption in platelets, endothelial cells, and erythrocytes in vitro and in vivo. The inhibition raises adenosine levels locally, activating platelet adenylate cyclase and cyclic-3',5'-adenosine monophosphate (cAMP) levels. This process inhibits platelet aggregation in response to stimuli such as platelet-activating factor (PAF), collagen, and adenosine diphosphate (ADP). Aspirin prevents platelet aggregation by irreversibly inhibiting platelet cyclooxygenase. This prevents the production of thromboxane A2, a potent inducer of aggregation and vasoconstriction.

Activase (Alteplase): Boehringer Ingelheim

Alteplase is a thrombolytic agent produced using recombinant DNA technology. It is FDA-approved for acute ischemic stroke. Alteplase is a fibrinolytic agent commonly known as a tissue plasminogen activator. Alteplase transforms plasminogen into plasmin, a proteolytic enzyme that lyses both fibrin and fibrinogen. Intravenous alteplase is largely eliminated by the liver, with an initial half-life of less than 5 minutes and a terminal half-life of 72 minutes.

Brilinta (Ticagrelor): AstraZeneca

Brilinta (Ticagrelor) is a P2Y12 receptor antagonist that inhibits the formation of thrombosis, lowering the risk of myocardial infarction and ischemic stroke. Brilinta reversibly binds to the ADP P2Y12 receptor, blocking ADP from binding. This can aid in the development of pathologic thrombus by blocking platelet activity and signal transmission. Because of the reversible binding, ticagrelor can be redistributed to newly formed platelets.

Emerging Therapies in the Ischemic Stroke Market

MultiStem: Athersys 

The MultiStem clinical product is generated from a particular class of stem cells known as Multipotent Adult Progenitor Cells (MAPC). MultiStem cell therapy works in numerous ways. The cells can express a variety of therapeutically relevant proteins and other factors, which have the potential to provide therapeutic benefits in a variety of ways, including reducing inflammation, protecting damaged or injured tissue, and promoting the formation of new blood vessels in areas of ischemic injury. These cells have a drug-like profile in that they predominantly produce substances that regulate the immune system, protect damaged or wounded cells, and promote tissue repair and healing. The cells are then eliminated from the body over time, just like a regular medication or biologic treatment.

Elezanumab: AbbVie

Elezanumab is an experimental monoclonal antibody that binds exclusively to repulsive guidance molecule A (RGMa) and is being tested for its efficacy after an ischemic stroke. RGMa is a neuronal growth and survival inhibitor that is overexpressed in the injured central nervous system after an acute ischemic stroke and other neuropathological conditions. Neutralizing RGMa is neuroprotective and promotes neuroplasticity in various preclinical models of neurodegeneration and injury, including acute ischemic stroke.

RNS60: Revalesio Corporation

RNS60 refers to a therapeutic drug under clinical development by Revalesio Corporation to treat ischemic stroke. RNS60 promotes intracellular signaling pathways that have anti-inflammatory effects while also promoting mitochondrial biogenesis, cell survival, and differentiation. In addition to protecting neurons and oligodendrocytes in the central nervous system, RNS60 regulates immune cell activity to restore cellular homeostasis throughout the body.

SB623: SanBio

SB623 is a patented Cell Therapy Medicine (MSC implantation) composed of modified and cultured adult bone marrow-derived mesenchymal stem cells that have undergone transient genetic modification. The implantation of SB623 cells into injured nerve tissue in the brain is intended to activate the brain's innate regeneration potential to restore lost motor functions.

ACT017: Acticor Biotech

ACT017 is a humanized monoclonal antigen-binding fragment (Fab) that targets the human platelet glycoprotein VI, a critical receptor for collagen and fibrin that promotes thrombus formation and stability. ACT017 is under development as an antiplatelet drug to treat the acute phase of ischemic stroke. ACT017 is expected to work by inhibiting the growth of clots, preventing downstream clotting in microvessels, and blocking cellular processes that involve platelet-neutrophil interactions and oxygen radical release.

Detailed list of emerging therapies in Ischemic Stroke is provided in the final report.

Leading Companies in the Ischemic Stroke Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global ischemic stroke market, several leading companies are at the forefront of developing integrated platforms to enhance the management of ischemic stroke. Some of the major players include AstraZeneca and Boehringer Ingelheim. These companies are driving innovation in the ischemic stroke market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

In November 2020, AstraZeneca declared that Brilinta (ticagrelor) had been authorized in the United States to lower the risk of stroke in individuals with high-risk transient ischemic attacks (TIAs) or acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5). The U.S. Food and Drug Administration (FDA) approved it based on positive results from the THALES Phase III trial, which showed that aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or TIA.

Key Players in Ischemic Stroke Market:

The key players in the Ischemic Stroke market who are in different phases of developing different therapies are Boehringer Ingelheim, AstraZeneca, Athersys, AbbVie, Revalesio Corporation, SanBio, Acticor Biotech, and others.

Regional Analysis:

The major markets for ischemic stroke include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for ischemic stroke while also representing the biggest market for its treatment. This can be attributed to the rising prevalence of stroke due to lifestyle and health conditions, such as hypertension, diabetes, excessive alcohol consumption, etc.

Moreover, numerous technological advancements, such as modern diagnostic tools, portable imaging devices, and novel thrombolytic agents, are improving early detection and treatment efficiency. The expansion of telemedicine services and mobile stroke units further enhances accessibility and timely intervention, reducing pre-hospital delays.

Apart from this, many leading companies are investing heavily in research to enhance knowledge of disease pathology and create innovative tools for illness detection and diagnosis that yield faster and more precise findings. The market is expanding more quickly due to government programs aimed at raising awareness and preventing strokes. Additionally, favorable reimbursement practices and regulatory assistance are also promoting innovation and the uptake of cutting-edge therapies.

Recent Developments in Ischemic Stroke Market:

• In July 2024, SanBio Co., Ltd. declared that the U.S. Patent and Trademark Office had published a Notice of Allowance for the patent application that SanBio, Inc. had submitted for SB623 (INN: vandefitemcel), its principal development product intended to treat chronic ischemic stroke.
• In February 2024, Revalesio presented topline findings from the completed Phase 2 RESCUE clinical trial of RNS60 (NCT04693715) in acute ischemic stroke patients during an oral presentation at the International Stroke Conference (ISC) 2024's Late-Breaking Science session. RNS60 met its key endpoints in RESCUE, which were safety and mortality.
• In October 2023, Athersys stated that the independent data safety monitoring board (DSMB) had completed a pre-planned interim review of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical study testing MultiStem for the treatment of acute moderate-to-severe ischemic stroke.

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ischemic stroke market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ischemic stroke market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current ischemic stroke marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800